Первая линия эндокринотерапии гормонопози-тивного HER2-негативного метастатического рака молочной железы. Время перемен после длительного затишья


Л.Г. Жукова, А.Г. Манихас

ФГБУ РОНЦ им. Н.Н. Блохина МЗ РФ, Москва
В течение последнего года мы наблюдаем изменение принципов эндокринотерапии гормонопозитивного рака молочной железы в целом, и первой линии в частности. В статье приведены результаты исследования 3-й фазы FALCON, доложенные в Копенгагене на конгрессе ESMO, подтвердившего преимущество фулвестранта в качестве первой линии эндокринотерапии в отношении выживаемости без прогрессирования по сравнению с существовавшим длительное время стандартным вариантом – применением ингибитора ароматазы – анастрозола.

Литература


1. Paridaens R.J., Dirix L.Y., Beex L.V., Nooij M., Cameron D.A., Cufer T., Piccart M.J., Bogaerts J., Therasse P. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J. Clin. oncol. 2008;26(30):4883–90.

2. Mouridsen H., Sun Y., Gershanovich M., Perez-Carrion R., Becquart D., Chaudri-Ross H.A., Lang R. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. Oncologist. 2004;9(5):489–96.

3. Milla-Santos A., Milla L., Portella J., Rallo L., Pons M., Rodes E., Casanovas J., Puig-Gali M. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am. J. Clin. Oncol. 2003;26(3):317–22.

4. Bonneterre J., Thürlimann B., Robertson J.F., Krzakowski M., Mauriac L., Koralewski P., Vergote I., Webster A., Steinberg M., von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J. Clin. Oncol. 2000;18(22):3748–57.

5. Finn R.S., Crown J.P., Lang I., et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.

6. Finn R.S., Martin M., Rugo H.S., Jones S., Im S.-A., Gelmon K.A., et al. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2-advanced breast cancer (ABC). J. Clin. Oncol. 2016;34(Suppl. Abstr.):507.

7. Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S., Gertler S.Z., May J.T., Burton G., Dimery I., Webster A., Morris C., Elledge R., Buzdar A. Double-blind, rando-mized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol. 2002;20(16):3386–95.

8. Howell A., Pippen J., Elledge R.M., Mauriac L., Vergote I., Jones S.E., Come S.E., Osborne C.K., Robertson J.F. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. Cancer. 2005;104(2):236–39.

9. Chia S., Gradishar W., Mauriac L., Bines J., Amant F., Federico M., Fein L., Romieu G., Buzdar A., Robertson J.F., Brufsky A., Possinger K., Rennie P., Sapunar F., Lowe E., Piccart M. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor–positive, advanced breast cancer: results from EFECT. J. Clin. Oncol. 2008;26(10):1664–70.

10. Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R., Verhoeven D., Pedrini J.L., Smirnova I., Lichinitser M.R., Pendergrass K., Garnett S., Lindemann J.P., Sapunar F., Martin M. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer. J. Clin. Oncol. 2010;28(30):4594–600.

11. Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R., Verhoeven D., Pedrini J.L., Smirnova I., Lichinitser M.R., Pendergrass K., Malorni L., Garnett S., Rukazenkov Y., Martin M. Final overall survival: Fulvestrant 500mg vs 250mg in the randomized CONFIRM trial. J. Natl. Cancer Inst. 2013;337.

12. Robertson J.F.R., Llombart-Cussac A., Rolski J., Feltl D., Dewar J., Macpherson E., Lindemann J., Ellis M.J. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J. Clin. Oncol. 2009;27(27):4530–35.

13. Robertson J.F.R., Lindemann J.P., Llombart-Cussac A., Rolski J., Feltl D., Dewar J., Emerson L., Dean A., Ellis M.J. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’study. Breast cancer research and treatment. 2012;э136(2):503–11.

14. Ellis M.J., Llombart-Cussac A., Feltl D., Dewar J.A., Jasiówka M., Hewson N., Rukazenkov Y., Robertson J.F. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J. Clin. Oncol. 2015;33(32):3781–87.

15. Ellis M.J., et al. FALCON: A Phase III randomised trial of fulvestrant 500 mgvs. anastrozole for hormone receptor-positive advanced breast cancer. LBA 14. ESMO 2016, Copenhagen.


Об авторах / Для корреспонденции


Л.Г. Жукова – д.м.н., в.н.с. отделения химиотерапии и комбинированного лечения злокачественных опухолей ФГБУ РОНЦ им. Н.Н. Блохина МЗ РФ, Москва; e-mail: zhukova.lyudmila@rambler.ru


Похожие статьи


Бионика Медиа